Extended Data Fig. 7: rescues LoF mutations of D1R.

\({{\rm{GEM}}}_{{\rm{ago}}-{\rm{PAM}}}^{{\rm{TM5}}/6/7}\) a, Schematic illustration of the therapeutic mechanism of \(\text{GE}{\text{M}}_{\text{ago}-\text{PAM}}^{\text{TM}5/6/7}\) for LoF mutations. b, Location and types of LoF mutations in D1R. c, The effect of \(\text{GE}{\text{M}}_{\text{ago}-\text{PAM}}^{\text{TM}5/6/7}\) on cAMP accumulation in the LoF mutant D1R. The relative efficacy is defined as the range between the maximal response (1 μM dopamine or with \(\text{GE}{\text{M}}_{\text{ago}-\text{PAM}}^{\text{TM}5/6/7}\)) and the vehicle baseline (no agonist). Values are shown as the mean ± SEM from three independent experiments performed in triplicate. ^NSP ≥ 0.05, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001 by two-way ANOVA followed by Sidak’s multiple comparisons test (P = 0.0683, <0.0001, <0.0001, <0.001, <0.001, <0.001, <0.001 from left to right). A detailed statistical evaluation is provided in Extended Data Table 6. Schematics in a,b were created in BioRender. Qin, J. (2025) https://BioRender.com/9l51ggt.